The European Medicines Agency and the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) launched ’ENCePP studies’. Building on the foundations of the ENCePP network of Excellence, ‘ENCePP studies’ is a seal for EU-based, benefit/risk or risk studies that are carried out in compliance with the ENCePP code of conduct for independence and transparency and its methodological research standards and are entered into a publicly available electronic register before their start.
Investigators who apply to conduct an ENCePP study commit to a maximum level of transparency with respect to relevant information regarding their investigation. This includes publication of study findings regardless of their positive or negative results and making public relevant information on the study protocol before the study commences.
The seal ‘ENCePP studies’ is a confirmation for the public that the study was conducted in adherence to the ENCePP research and methodological principles and will increase trust in the robustness of the findings.
‘ENCePP studies’ is an important milestone for ENCePP, the European network of excellence in the fields of pharmacoepidemiology and pharmacovigilance. It builds on some of the network’s main achievements since 2007, specifically the adoption of an ENCePP Code of Conduct and the development of a checklist of methodological standards for ENCePP study protocols.
The ENCePP Code of Conduct is a set of rules and principles to ensure transparency and promote scientific independence. The Code is voluntary and lays down rights and obligations between investigators and study funders detailing their responsibilities in the conduct of studies. It covers aspects such as the development of the study protocol, the conduct of the study, data ownership, and access to data and publication of the results. In order to facilitate compliance with the transparency requirement outlined in the Code, the Agency is developing an electronic-register of studies, which will provide a publicly accessible resource for the registration and consultation of pharmacoepidemiological and pharmacovigilance studies.
The checklist of methodological standards for ENCePP study protocols is aimed at stimulating researchers to address important epidemiological principles when designing a pharmacoepidemiological study and writing a study protocol. Adherence to these principles will promote transparency regarding methodologies used in pharmacoepidemiological studies performed in the EU. It will also increase awareness of new developments in science and methodology in the field of pharmacoepidemiology.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.